| Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients J Vidal, L Muinelo, A Dalmases, F Jones, D Edelstein, M Iglesias, M Orrillo, ... Annals of Oncology 28 (6), 1325-1332, 2017 | 325 | 2017 |
| Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised … CS Fuchs, K Shitara, M Di Bartolomeo, S Lonardi, SE Al-Batran, ... The Lancet Oncology 20 (3), 420-435, 2019 | 227 | 2019 |
| Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer BO Van Emburgh, S Arena, G Siravegna, L Lazzari, G Crisafulli, G Corti, ... Nature communications 7 (1), 13665, 2016 | 203 | 2016 |
| Concordance of blood-and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer J Grasselli, E Elez, G Caratù, J Matito, C Santos, T Macarulla, J Vidal, ... Annals of Oncology 28 (6), 1294-1301, 2017 | 192 | 2017 |
| Efficacy of Sym004 in patients with metastatic colorectal cancer with acquired resistance to anti-EGFR therapy and molecularly selected by circulating tumor DNA analyses: a … C Montagut, G Argilés, F Ciardiello, TT Poulsen, R Dienstmann, M Kragh, ... JAMA oncology 4 (4), e175245-e175245, 2018 | 109 | 2018 |
| Immune checkpoint inhibition in colorectal cancer: microsatellite instability and beyond R Cohen, B Rousseau, J Vidal, R Colle, LA Diaz, T André Targeted oncology 15, 11-24, 2020 | 81 | 2020 |
| The first-in-class anti-EGFR antibody mixture Sym004 overcomes cetuximab resistance mediated by EGFR extracellular domain mutations in colorectal cancer FJ Sánchez-Martín, B Bellosillo, M Gelabert-Baldrich, A Dalmases, ... Clinical Cancer Research 22 (13), 3260-3267, 2016 | 69 | 2016 |
| Clinical impact of presurgery circulating tumor DNA after total neoadjuvant treatment in locally advanced rectal cancer: a biomarker study from the GEMCAD 1402 trial J Vidal, D Casadevall, B Bellosillo, C Pericay, R Garcia-Carbonero, ... Clinical Cancer Research 27 (10), 2890-2898, 2021 | 54 | 2021 |
| Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations JS Brammeld, M Petljak, I Martincorena, SP Williams, LG Alonso, ... Genome research 27 (4), 613-625, 2017 | 36 | 2017 |
| Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patients J Vidal, S Clave, S de Muga, I González, L Pijuan, J Gimeno, J Remon, ... Journal of Thoracic Oncology 9 (12), 1816-1820, 2014 | 34 | 2014 |
| ROS1 copy number alterations are frequent in non-small cell lung cancer S Clavé, J Gimeno, AM Muñoz-Mármol, J Vidal, N Reguart, E Carcereny, ... Oncotarget 7 (7), 8019, 2016 | 33 | 2016 |
| Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy J Vidal, B Bellosillo, CS Vivas, P García-Alfonso, A Carrato, MT Cano, ... Annals of Oncology 30 (3), 439-446, 2019 | 27 | 2019 |
| ctDNA to guide adjuvant therapy in localized colorectal cancer (CRC) L Masfarré, J Vidal, C Fernández-Rodríguez, C Montagut Cancers 13 (12), 2869, 2021 | 26 | 2021 |
| Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies D Azuara, C Santos, A Lopez-Doriga, J Grasselli, M Nadal, X Sanjuan, ... Molecular Cancer Therapeutics 15 (5), 1106-1112, 2016 | 21 | 2016 |
| Dynamic treatment stratification using ctDNA J Vidal, A Taus, C Montagut Tumor Liquid Biopsies, 263-273, 2020 | 19 | 2020 |
| Liquid biopsy for precision adjuvant chemotherapy in colon cancer C Montagut, J Vidal New England Journal of Medicine 386 (24), 2330-2331, 2022 | 18 | 2022 |
| SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021) J Capdevila, MA Gómez, M Guillot, D Páez, C Pericay, MJ Safont, ... Clinical and Translational Oncology 24 (4), 646-657, 2022 | 12 | 2022 |
| Hypersensitivity reaction caused by folinic acid administration: a case report and literature review M Florit-Sureda, D Conde-Estévez, J Vidal, C Montagut Journal of Chemotherapy 28 (6), 500-505, 2016 | 12 | 2016 |
| Liquid biopsy detects early molecular response and predicts benefit to first-line chemotherapy plus cetuximab in metastatic colorectal cancer: PLATFORM-B study J Vidal, MC Fernández-Rodríguez, D Casadevall, P García-Alfonso, ... Clinical Cancer Research 29 (2), 379-388, 2023 | 11 | 2023 |
| Evolution of heterogeneous mechanisms of acquired resistance to cetuximab-based therapy in colorectal cancer. C Montagut, B Bellosillo, I Gonzalez, A Martinez, A Dalmases, M Iglesias, ... Journal of Clinical Oncology 32 (15_suppl), 3526-3526, 2014 | 10 | 2014 |
